OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study

The total annual IPF-related costs were obtained as the sum of direct health costs, direct non-health costs and indirect costs. IPF-related costs were quantified for each patient over the follow-up period of 12 months. The direct health and direct non-health costs were calculated as the sum of the costs of medical visits, emergency room visits, hospital admissions, outpatient tests, non-pharmacological treatments and pharmacological treatments and the sum of transport costs, paid caregivers costs, orthopedic material costs, financial aid, and structural changes cost. The indirect costs included number of IPF related days off work and time dedicated to patient care with IPF (informal caregiver). The opportunity cost method was used to calculate informal care costs. The indirect costs were estimated by applying salary costs based on the latest data published by the Spanish Instituto Nacional de Estadística from the salary structure survey, adjusted to age.

The Quality of Life of patients with IPF according to Forced Vital Capacity (FVC)% predicted value, is assessed through SGRQ. The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms (frequency and severity of respiratory symptoms), activity (limitations due to dyspnoea) and impact (psychological and social functioning disorders caused by the disease). The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life). The number of participants analysed displays the number of participants with available data at the timepoint of interests.

The Quality of Life of patients with IPF according to Forced Vital Capacity (FVC)% predicted value is assessed through the EQ-VAS, which is a self-rated health status using a visual analogue scale (VAS), ranging form 0-100, with 0 = worst state of health imaginable and 100 = best state of health imaginable. The EQ-VAS is part of the EuroQoL five dimensions questionaire 5L (EQ-5D-5L).

The number of participants analysed displays the number of participants with available data at the timepoint of interests.

The Quality of Life of patients with IPF according to Forced Vital Capacity (FVC)% predicted value is assessed through the Barthel Index.

Barthel Index were used to score the ability of a participant to care for himself. It consists of 10 items, the values assigned to each item are based on time and amount of actual physical assistance required if a participant is unable to perform the activity. The final score ranges from 0 and 100. Participant scoring 100 is continent, feeds himself, dresses himself, gets up out of bed and chairs, bathes himself, walks at least a block, and can ascend and descend stairs.

The number of participants analysed displays the number of participants with available data at the timepoint of interests.

Number of IPF-patients with acute exacerbations according to Forced Vital Capacity (FVC)% that occured along one year.

Acute exacerbation is defined as an acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality.

The total annual acute exacerbation-related costs were obtained as the sum of direct and indirect costs for each patient over the follow-up period of 12 months.

For estimation of costs the following variables were used: Acute exacerbation related resource use for direct cost estimation: primary and secondary care visits, emergency visits (primary care and hospital), hospitalizations, ICU with and without intubation (qualitative analysis), outpatient tests and other examinations, use of transport, use of formal caregiver, pharmacological and non-pharmacological treatments (except treatments administered in hospitalization), orthopedic material, formal social services, economic aid and structural adaptations. Acute exacerbation related resource use for indirect cost estimation: patients' days off work and informal caregiver.

Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%.

FVC decline is calculated: FVC% (T12)- FVC%(T0)).

In order to estimate the direct and indirect costs according to FVC decline the following variable were described:

FVC predicted along the study. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253)

(FVC is FVC in liters, T is height in cm and E is age in years)

The calculated variable was stratified into the following subgroups between T0 and T12:

≤-10%; from -10% to -5%; >-5%

Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%.

FVC decline is calculated: FVC% (T12)- FVC%(T0)).

In order to estimate the direct and indirect costs according to FVC decline the following variable were described:

FVC predicted along the study. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253)

(FVC is FVC in liters, T is height in cm and E is age in years)

The calculated variable was stratified into the following subgroups between T0 and T12:

≤-10%; from -10% to -5%; >-5%

Results are reported for participants with predicted FVC <50% at baseline.

Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%.

FVC decline is calculated: FVC% (T12)- FVC%(T0)).

In order to estimate the direct and indirect costs according to FVC decline the following variable were described:

Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253)

(FVC is FVC in liters, T is height in cm and E is age in years)

The calculated variable was stratified into the following subgroups between T0 and T12:

≤-10%; from -10% to -5%; >-5%

Results are reported for participants with predicted FVC 50-80% at baseline.

Economic Impact of IPF in adult patients through the estimation annual direct and indirect costs associated with the disease (€/year) from a social perspective by FVC decline according to predicted FVC%.

FVC decline is calculated: FVC% (T12)- FVC%(T0)).

In order to estimate the direct and indirect costs according to FVC decline the following variable were described:

Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253)

(FVC is FVC in liters, T is height in cm and E is age in years)

The calculated variable was stratified into the following subgroups between T0 and T12:

≤-10%; from -10% to -5%; >-5%

Results are reported for participants with predicted FVC > 80% at baseline.

Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12).

The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms, activity and impact. The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life).

FVC decline: FVC% (T12)- FVC%(T0)

In order to estimate the Quality of Life according to FVC decline the following variable were described:

FVC % predicted along the study:. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253)

(FVC is FVC in liters, T is height in cm and E is age in years).

The calculated variable was stratified into the following subgroups between T0 and T12:

≤-10%; from -10% to -5%; >-5%

Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12).

The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms, activity and impact. The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life).

FVC decline: FVC% (T12)- FVC%(T0)

In order to estimate SGRQ according to FVC decline the following variable were described:

Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253)

(FVC is FVC in liters, T is height in cm and E is age in years).

The calculated variable was stratified into the following subgroups between T0 and T12:

≤-10%; from -10% to -5%; >-5%

Results are reported for participants with predicted FVC<50% at baseline.

Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12).

The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms (frequency and severity of respiratory symptoms), activity (limitations due to dyspnoea) and impact (psychological and social functioning disorders caused by the disease). The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life).

FVC decline: FVC% (T12)- FVC%(T0)

Results are reported for participants with predicted FVC 50-80% at baseline.

Absolute Change in SGRQ score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12).

The SGRQ is a 50-item questionaire developed to quantify the impact of the disease on the health and QoL perceived by patients with respiratory diseases. It consisted of 50 items divided into 3 scales: symptoms (frequency and severity of respiratory symptoms), activity (limitations due to dyspnoea) and impact (psychological and social functioning disorders caused by the disease). The final scores ranged from 0 (best health-related quality of life) to 100 (worse health-related quality of life).

FVC decline: FVC% (T12)- FVC%(T0)

Results are reported for participants with predicted FVC >80% at baseline.

Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12). The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health.

FVC decline: FVC% (T12)- FVC%(T0)

In order to estimate the EQ-VAS according to FVC decline the following variable were described:

FVC % predicted along the study:

Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253)

(FVC is FVC in liters, T is height in cm and E is age in years)

The calculated variable was stratified into the following subgroups between T0 and T12:

≤-10%; from -10% to -5%; >-5%

Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12).

The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health.

FVC decline: FVC% (T12)- FVC%(T0)

In order to estimate the EQ-VAS according to FVC decline the following variable were described:

FVC % predicted along the study:

Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years)

The calculated variable was stratified into the following subgroups between T0 and T12:

≤-10%; from -10% to -5%; >-5% Results are reported for participants with predicted FVC<50% at baseline.

Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12).

The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health.

FVC decline: FVC% (T12)- FVC%(T0)

In order to estimate the EQ-VAS according to FVC decline the following variable were described:

FVC % predicted along the study:. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years)

The calculated variable was stratified into the following subgroups between T0 and T12:

≤-10%; from -10% to -5%; >-5% Results are reported for participants with predicted FVC 50-80% at baseline.

Absolute Change in EQ-VAS score by FVC decline according to predicted FVC% from baseline visit (T0) to 12 month visit (T12).

The EQVAS is a self-rated health status using a VAS (0-100), with 0= worst state of health imaginable and 100= best state of health imaginable. The EQ-VAS records the subject's perceptions of their own current overall health.

FVC decline: FVC% (T12)- FVC%(T0)

In order to estimate the EQ-VAS according to FVC decline the following variable were described:

FVC % predicted along the study:. Men: FVC % predicted (%) = 100 FVC / (0.0678 T - 0.0147 E - 6.0548) Women: FVC % predicted (%) = 100 FVC / (0.0454 T - 0.0211 E - 2.8253) (FVC is FVC in liters, T is height in cm and E is age in years)

The calculated variable was stratified into the following subgroups between T0 and T12:

≤-10%; from -10% to -5%; >-5% Results are reported for participants with predicted FVC>80% at baseline.

Caregivers of IPF patients were asked to complete the Zarit Burden Interview. It is a self-report measure. The revised version contains 22 items. Each item on the interview is a statement which the caregiver is asked to endorse using a 5-point scale. Response options, in the Spanish version, range from 0 (never) to 4 (nearly always).

The final score ranges from 0 to 88. A higher score implies a greater burden (≤ 21: Little or no burden; 22-40: mild to moderate burden; 41-60: moderate to severe burden; ≥ 61: severe burden).